Pharmaceuticals
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
SHANGHAI and GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors (the "Board") has authorized...
2021-07-29 20:00
7217
HanAll Biopharma Reports Second Quarter 2021 Results
* Q2'21 sales of KRW 23.4 billion increased 4% from the same period last year * Q2'21 operating profit of KRW 1.6 billion fell slightly by 3% compared to Q2'20 * H1'21 sales of KRW 51.2 billion and operating profit of 6.3 billion grew by 15% and 56% YoY [Business Performance and Financial St...
2021-07-29 18:44
10880
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial
- Improvement of symptoms such as cough and dyspnea in mild patients over age 50 was reported to be as twice as fast and statistically significant in the treatment group (4 days) compared to the placebo control group (9 days). - Development is underway for potential combination therapies and nove...
2021-07-29 18:00
1326
Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial
SYDNEY, July 28, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant pr...
2021-07-28 21:08
1533
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
* Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase1b/2 trial in South Korea * Efineptakin alfa in patients with GBM showed a 83.3% survival ratio over one year in a phase 1 trial in the U.S. SHANGHAI and GAITHERSBURG, Md., July 28, 20...
2021-07-28 19:15
4317
Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China
SUZHOU, China, July 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has dosed the first batch of subjects in its phase I clinical trial of...
2021-07-28 13:47
5080
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
SHANGHAI and GAITHERSBURG, Md., July 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that onJuly 27, 2021, the Board of Directors of the Comp...
2021-07-27 20:35
11413
PharmAbcine to Present at H.C Wainwright Ophthalmology Virtual Conference
DAEJEON, South Korea, July 26, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the company is invited to deliver a video presentation at H.C Wainwright Ophthalmolo...
2021-07-26 20:00
1449
HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 26, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumo...
2021-07-26 19:11
4667
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order ...
2021-07-21 22:00
11586
Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy
* Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND * Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service INCHEON, South Korea and SEATTLE, July 20, 2021 /PRNewswire/ -- Sams...
2021-07-20 20:00
1432
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
SUZHOU, China, July 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced thatParaguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emerg...
2021-07-16 14:41
36485
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function
MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced thatMovement Disorders, the official jou...
2021-07-15 21:52
36658
Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa
SUZHOU, China, July 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ("Fosun Pharma Development"), on the commercialisation of proxalutamide for the treatment of CO...
2021-07-15 10:00
34021
Johnson & Johnson Innovation announces extension of innovation partnering office at Monash University in collaboration with Victorian State Government to accelerate the life-sciences hub
- Victorian State Government extends financing of JJIPO@Monash for an additional two years - Extension will further boost Victorian hub for researchers and early-stage companies to connect with industry experts and deliver novel healthcare solutions MELBOURNE, Australia, July 15, 2021 /PRNewswi...
2021-07-15 10:00
1431
Nippon Express Italia Acquires GDP Certification for Company-owned Warehouse near Milan Malpensa Airport
TOKYO, July 14, 2021 /PRNewswire/ -- Nippon Express Italia S.P.A. (hereinafter " NE Italy"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification from the certification body CERTIQUALITY S.r.l., effectiveMay 25, for its company-owned warehouse nea...
2021-07-14 15:00
1299
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne
SUZHOU, China, July 13, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small-molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug...
2021-07-14 07:05
17735
Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US
SUZHOU, China, July 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide's phase...
2021-07-11 21:03
19677
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the signing of two new collaborations with emerging biote...
2021-07-09 20:00
30033
Sequanta and Mission Bio announce strategic partnership
SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainl...
2021-07-09 15:44
1806
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5203
